BioCryst Pharmaceuticals, Inc. (BCRX) Seems To Be Turning Some Investors Off

BioCryst Pharmaceuticals, Inc. (BCRX) has seen some recent activity in the stock market and its common shares closed trading at $4.2300 yesterday. People are starting to take notice of BCRX as the common shares traded as high as $4.4950 and as low as $4.2100 in the previous trading session.

BioCryst Pharmaceuticals, Inc. (BCRX) average trading volume is 8.81M. However, in the previous trading session BioCryst Pharmaceuticals, Inc. (BCRX) exchanged 6,100,635 shares. The 1st support level on BCRX is $3.89 and the 1st upside resistance level on BCRX is $6.17. BCRX fifty day moving average is $4.6857 and BCRX 200 day moving average is $3.6583.

BioCryst Pharmaceuticals, Inc. (BCRX) current performance has been indicated by the recent movement in BCRX common shares. BCRX has performed -14.55% over the past 30 days, BCRX has performed 7.09% over the past 3 months and BCRX has shown 48.94% over the past year. BioCryst Pharmaceuticals, Inc. (BCRX) has a 52 week range of $1.3800 to $6.2900. BioCryst Pharmaceuticals, Inc. (BCRX) is trading 206.52% from its 52 week low and -32.71% from its 52 week high. BioCryst Pharmaceuticals, Inc. (BCRX) is indicating a 22.96% short float indicating the amount short in the float.

BCRX has 154.16M shares outstanding and 135.46M shares in the float. BioCryst Pharmaceuticals, Inc. (BCRX) presently has a market cap of $758.99M and income of -115.40M. The EPS next quarter for BCRX is -0.26 and projected EPS next year is 15.60%. The market cap of BioCryst Pharmaceuticals, Inc. (BCRX) at $758.99M represents how many People own shares of BCRX and is based off the last price ($4.2300) of BCRX and the amount of shares outstanding (154.16M) with BioCryst Pharmaceuticals, Inc. (BCRX).

BioCryst Pharmaceuticals, Inc. (BCRX) has total cash (mrq) of 113.06M, total cash per share (mrq) of 0.73, total debt of BCRX is at 85.24M and total debt/equity (mrq) is 2,336.62. . BioCryst Pharmaceuticals, Inc. (BCRX) operational cash flow (ttm) is -85.87M, BCRX leveraged free cash flow (ttm) is -47.2M.

BCRX is trading -12.72% below (bearish) its SMA20, -9.29% below (bearish) its SMA50 and 27.32% above (bullish) its SMA200.

Related Articles

Zebra (NASDAQ: ZBRA) And XMReality Inks Partnership Agreement

Zebra Technologies Corporation (NASDAQ: ZBRA) and XMReality publicized that the two have signed an agreement to work together and collaborate on ideas that offer...

Elanco (NYSE: ELAN) Launch Public Offering Of Common Stock

Elanco Animal Health Inc. (NYSE: ELAN) shares that it is planning to commence the public offering of 54,500,000 shares of common stock. It will...

Jacobs (NYSE: J) Partners with PA Consulting

Jacobs Engineering Group, Inc. (NYSE: J), a famous construction company announced that it will be collaborating with PA Consulting. The firm has purchased an...

Get in Touch

19,000FansLike
35,222FollowersFollow
22,458FollowersFollow

Latest Posts

Zebra (NASDAQ: ZBRA) And XMReality Inks Partnership Agreement

Zebra Technologies Corporation (NASDAQ: ZBRA) and XMReality publicized that the two have signed an agreement to work together and collaborate on ideas that offer...

Elanco (NYSE: ELAN) Launch Public Offering Of Common Stock

Elanco Animal Health Inc. (NYSE: ELAN) shares that it is planning to commence the public offering of 54,500,000 shares of common stock. It will...

Jacobs (NYSE: J) Partners with PA Consulting

Jacobs Engineering Group, Inc. (NYSE: J), a famous construction company announced that it will be collaborating with PA Consulting. The firm has purchased an...

Fuwei (NASDAQ: FFHL) Plans To Sell Dornier Production Line

Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL) recently declared that it will be closing its Dornier line of production as early as possible. Fuwei...

PPG Industries (NYSE: PPG) Announces Accquisition Of Ennis-Flint

PPG Industries, Inc. (NYSE: PPG) is planning to buy Ennis-Flint in a deal valued at nearly $1.15 billion. The decision to acquire Ennis-Flint will...